Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | GLS | O94925 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29820228 | 1.00 | CTSB (0.56) | CTSBCTSSCTSKGLSLMNA | |
| SCHEMBL11892876 | 0.91 | CTSB (0.51) | CTSBCTSSCTSKGLSLMNA | |
| SCHEMBL22452353 | 0.88 | CTSB (0.54) | CTSBCTSSCTSKGLSLMNA | |
| SCHEMBL904075 | 0.86 | CTSK (0.54) | CTSBCTSSCTSKNPC1NAMPT | |
| SCHEMBL31457033 | 0.86 | CTSK (0.54) | CTSBCTSSCTSKNPC1NAMPT | |
| SCHEMBL30192965 | 0.85 | GLS (0.55) | GLSKDM4ABRD4CREBBPNAMPT | |
| SCHEMBL851272 | 0.85 | GLS (0.55) | GLSKDM4ABRD4CREBBPNAMPT | |
| SCHEMBL15244746 | 0.85 | CTSB (0.48) | CTSBCTSSCTSKGLSLMNA | |
| SCHEMBL29402185 | 0.84 | KDM4A (0.46) | CTSBCTSSCTSKGLSLMNA | |
| SCHEMBL6228914 | 0.84 | LMNA (0.58) | LMNAHPGDMTORNPC1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | CELLARITY, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| WO-2025096981-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | CELLARITY, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-04-17 | — | — | US | disclosed |
| CN-119654324-A | Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same | 株式会社次代生物科学 | 2025-03-18 | — | — | CN | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1187825-A1 | THIOPHENE INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2002-03-20 | — | — | EP | disclosed |
| US-6352982-B1 | TREATING DIABETES, OBESITY, OR INVETERATE DIARRHEA IN A MAMMAL WHICH COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF A COMPOUND OF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6274620-B1 | 2-BENZENESULFONYLAMINO-3-((5-BROMO-THIOPHENE-2-CARBONYL)-AMINO )PROPIONIC ACID-TERT-BUTYL ESTERS AS ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; OSTEOPOROSIS, RESTENOSIS, AND OCULAR NEOVASCULARIZATION | BIOCHEM PHARMA INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-2000075129-A1 | THIOPHENE INTEGRIN INHIBITORS | SHIRE BIOCHEM INC. (CA) | 2000-12-14 | — | — | WO | disclosed |
| CN-1252795-A | 4, 1-benzoxazepine *, their analogs and their use as somatostatin agonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-05-10 | — | — | CN | disclosed |
| EP-0979227-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998047882-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-29 | — | — | WO | disclosed |
| US-5541286-A | Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids | SCIOS NOVA INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5444048-A | Antiinflammatory agents, analgesics | SCIOS NOVA, INC. (US) | 1995-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | CTSB 1031/4885CTSS 1065/4885CTSK 1212/4885 |
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CTSB 2160/4885CTSS 2346/4885CTSK 1862/4885 |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | CTSB 3956/4885CTSS 4223/4885CTSK 4249/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | CTSB 52/4885CTSS 39/4885CTSK 93/4885 |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | CTSB 3956/4885CTSS 4223/4885CTSK 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.